Effects of -Glucans Ingestion on Alveolar Bone Loss, Intestinal Morphology, Systemic Inflammatory Profile, and Pancreatic -Cell Function in Rats with Periodontitis and Diabetes

This study aimed to evaluate the effects of -glucan ingestion (Saccharomyces cerevisiae) on the plasmatic levels of tumor necrosis factor- (TNF-alpha) and interleukin-10 (IL-10), alveolar bone loss, and pancreatic beta-cell function (HOMA-BF) in diabetic rats with periodontal disease (PD). Besides, intestinal morphology was determined by the villus/crypt ratio. A total of 48 Wistar rats weighing 203 +/- 18 g were used. Diabetes was induced by the intraperitoneal injection of streptozotocin (80 mg/kg) and periodontal inflammation, by ligature. The design was completely randomized in a factorial scheme 2 x 2 x 2 (diabetic or not, with or without periodontitis, and ingesting beta-glucan or not). The animals received beta-glucan by gavage for 28 days. Alveolar bone loss was determined by scanning electron microscopy (distance between the cementoenamel junction and alveolar bone crest) and histometric analysis (bone area between tooth roots). beta-glucan reduced plasmatic levels of TNF-alpha in diabetic animals with PD and of IL-10 in animals with PD (p < 0.05). beta-glucan reduced bone loss in animals with PD (p < 0.05). In diabetic animals, beta-glucan improved beta-cell function (p < 0.05). Diabetic animals had a higher villus/crypt ratio (p < 0.05). In conclusion, beta-glucan ingestion reduced the systemic inflammatory profile, prevented alveolar bone loss, and improved beta-cell function in diabetic animals with PD.